ArticleFrontiers in immunology2026
IFN-γ-dominant immune shift is associated with reduced protective ILC2 responses in chronic kidney disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) progression is driven by an imbalance between inflammatory injury and tissue repair; however, the immune mechanisms that disrupt reparative pathways remain incompletely understood. Group 2 innate lymphoid cells (ILC2s) play protective roles in epithelial integrity and antifibrotic responses in the kidney, yet the signals that limit their maintenance during chronic inflammation are unclear. In this study, we investigated whether interferon-γ (IFN-γ)-dominant immune polarization is associated with the loss of renal ILC2s and exacerbation of CKD. Using a murine model of adenine-induced CKD, administration of α-galactosylceramide (αGalCer), a glycolipid known to activate invariant NKT cells, exacerbated renal dysfunction and tubulointerstitial injury. This was accompanied by enhanced inflammatory responses and a shift toward a type 1-dominant immune milieu. Notably, αGalCer treatment was associated with reduced renal ILC2 and regulatory T cell abundance, along with suppression of type 2 cytokines. Time-course analysis revealed a rapid and transient increase in renal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.